ClinicalTrials.gg
CompletedNCT07472361Updated Apr 22, 2026

A Study of ENX-104 in Healthy Participants

A Phase 1 interventional study of ENX-104 and ENX-104 in Healthy Volunteers, sponsored by Engrail Therapeutics INC. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Engrail Therapeutics INC · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The study is designed to evaluate the relative bioavailability, safety, and tolerability of a single dose of ENX-104 administered orally as a solution fasted, a tablet fasted, or a tablet with a high fat meal in healthy participants

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Engrail Therapeutics INC is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Biologically female participants (defined as assigned female at birth): a) Of non-, (Note: For female participants with Follicle-Stimulating Hormone [FSH] levels that are not consistent with status, enrollment will be at the Investigator's discretion and will require a negative pregnancy test Screening and Admission [Day -1]); b) Of childbearing potential and willing to use highly effective methods of , from Screening until 180 days after the last exposure to study drug, and with a negative pregnancy test at Screening and Admission (Day -1); c) Not currently breastfeeding or lactating, and not intending to initiate breastfeeding during the course of study conduct
  • Biologically male participants (defined as assigned male at birth), if fertile, must be willing to use highly effective contraception, from first Screening through to 3 months after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Is unable or unwilling to comply with the requirements of the study or, in the opinion of the Investigator or Sponsor, should not participate in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Treatment 1

    Drug: ENX-104

  • Experimental
    Treatment 2

    Drug: ENX-104

  • Experimental
    Treatment 3

    Drug: ENX-104

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of ENX-104

    Time frame: Up to Day 16

Secondary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 22

  2. Plasma Concentration of Metabolites of ENX-1014

    Time frame: Up to Day 16

07

Study locations

1 site
  • Parexel London EPCU
    Middlesex, London HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Mar 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 16, 2026
StartActual
Feb 25, 2026
Primary completionActual
Mar 19, 2026
CompletionActual
Mar 19, 2026
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07472361
Lead sponsor
Engrail Therapeutics INC
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
Feb 25, 2026
Primary completion
Mar 19, 2026
Completion
Mar 19, 2026
Last update
Apr 22, 2026

Study contacts

David George Steel, MBChB
principal investigator · Parexel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ENX-104

Start the discussion